Ernexa Therapeutics(NASDAQ) ERNAW

Market CapN/A

Since IPO (2026)-75%

5 YearN/A

1 YearN/A

1 Month-30%

$0.03

-9.64%

-0.00Today

Ernexa Therapeutics last closing stock price
Metric	Price	Date
Last close	USD 0.03	2026-10-14

Ernexa Therapeutics stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-27.51%	USD 0.03	2026-10-07
1 month	-30.11%	USD 0.04	2026-09-14
3 month	-68.34%	USD 0.08	2026-07-16
Since inception	-74.7%	USD 0.10	2026-02-06

Ernexa Therapeutics Financials at a Glance

Market Cap

N/A

Revenue (TTM)

$0.00

Net Income (TTM)

-$12.26M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

3.85 (High)

Dividend

$0.00

Beta (Volatility)

3.85 (High)

Price

$0.03

Volume

17,180

Open

$0.03

Price

$0.03

Volume

17,180

Open

$0.03

Previous Close

$0.03

Daily Range

$0.03 - $0.04

52-Week Range

$0.02 - $0.23

Estimated Earnings Date

Nov 11, 2026

Dividend

$0.00

Beta (Volatility)

3.85 (High)

Price

$0.03

Volume

17,180

Open

$0.03

Previous Close

$0.03

Daily Range

$0.03 - $0.04

52-Week Range

$0.02 - $0.23

Estimated Earnings Date

Nov 11, 2026

ERNAW News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Ernexa Therapeutics

Ernexa Therapeutics Inc. is a biotechnology company focused on developing innovative therapies utilizing induced mesenchymal stem cells (iMSC) to address solid tumors and autoimmune diseases. The company is advancing its lead product, ERNA-101, aimed at treating ovarian cancer, alongside ERNA-102, which targets rheumatoid arthritis.

Products and Services

ERNA-101: iMSC therapy for ovarian cancer
ERNA-102: iMSC therapy for rheumatoid arthritis
Licensing agreement with Factor Bioscience Limited

Growth Outlook

Strong pipeline with two promising iMSC therapies in development
Recent licensing agreement enhances research capabilities
Potential market expansion in oncology and autoimmune sectors

Financial Highlights

Recent quarterly net income of -$5.5 million
Cash and short-term investments of $9.2 million as of March 2026
Current ratio of 2.01 indicates strong liquidity position

Ernexa Therapeutics operates in the preclinical phase, focusing on groundbreaking therapies that leverage the potential of stem cell technology. The company’s lead product, ERNA-101, is designed to secrete pro-inflammatory cytokines, which may enhance the immune response against ovarian cancer. Meanwhile, ERNA-102 aims to deliver anti-inflammatory cytokines to mitigate the effects of rheumatoid arthritis. The growth outlook for Ernexa Therapeutics appears promising, bolstered by a strong pipeline and a recent licensing agreement that may enhance its research capabilities. The company is positioned to tap into the expanding markets of oncology and autoimmune diseases, which are increasingly prioritized in healthcare. Financially, Ernexa Therapeutics reported a net income loss of $5.5 million in the most recent quarter, reflecting the typical challenges faced by preclinical biotechnology firms. However, the company maintains a solid liquidity position with $9.2 million in cash and short-term investments, supported by a current ratio of 2.01. This indicates that Ernexa Therapeutics is well-equipped to fund its ongoing research and development efforts as it seeks to bring its innovative therapies to market.

AI Generated • Oct 4, 2026

Industry

Biotechnology

Sector

Health Care

Headquarters

Cambridge, MA 02141, US

ERNAW Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-305.85%

Return on Capital

-322.35%

Return on Assets

-194.09%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/A

Shares Outstanding

Volume

17.18K

Avg. Volume

22.10K

Financials (TTM)

Gross Profit

-$86.00K

Operating Income

-$11.74M

EBITDA

-$17.37M

Operating Cash Flow

-$8.84M

Capital Expenditure

-$42.00K

Free Cash Flow

-$8.88M

Cash & ST Invst.

$5.03M

Total Debt

$349.00K

Ernexa Therapeutics Performance Analysis

Ernexa Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	N/A
Q4	2025-12-31	N/A
Q1	2026-03-31	N/A
Q2	2026-06-30	N/A

Ernexa Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	75.4%
Q4	2025-12-31	-26.7%
Q1	2026-03-31	-46.3%
Q2	2026-06-30	51.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

N/A

Market Cap/Employee

N/A

Employees

N/A

Net Income

-$4.01M

-27.7%

EBITDA

-$3.97M

-28.7%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

$5.03M

+16.5%

Total Debt

$349.00K

-41.1%

Accounts Receivable

$83.00K

-46.1%

Inventory

$0.00

N/A

Long Term Debt

$182.00K

-51.6%

Short Term Debt

$167.00K

-23.0%

Return on Assets

-1.94%

N/A

Return on Invested Capital

-3.47%

N/A

Free Cash Flow

-$4.16M

-64.1%

Operating Cash Flow

-$4.15M

-64.0%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

^GSPCS&P 500

^GSPCS&P 500$7,709.28-0.01%

^DJIDJI

^DJIDJI$51,466.30-0.00%

^IXICNASDAQ

^IXICNASDAQ$26,684.28-0.02%

BTCBitcoin

BTCBitcoin$81,564.00-0.02%

SPCXSPCX

SPCXSPCX$152.06-0.03%

AAPLAAPL

AAPLAAPL$342.68+0.00%

AMZNAMZN

AMZNAMZN$253.61-0.02%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

NVDANvidia

NVDANvidia$221.30-3.16%

BACBank of America

BACBank of America$51.39-4.76%

CRWVCoreWeave

CRWVCoreWeave$65.78-15.46%

SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF

SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF$110.54-13.35%

INTCIntel

INTCIntel$98.12-4.56%

CIFRCipher Digital

CIFRCipher Digital$9.94-12.35%

SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF

SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF$42.52+13.63%

Questions About ERNAW

What is the current price of Ernexa Therapeutics?

Ernexa Therapeutics is trading at $0.03 per share.

What is the 52-week range for Ernexa Therapeutics?

Over the past 52 weeks, Ernexa Therapeutics has traded between $0.02 and $0.23.

How much debt does Ernexa Therapeutics have?

Ernexa Therapeutics total debt is unavailable.

How much cash does Ernexa Therapeutics have on hand?

Ernexa Therapeutics does not have cash on hand data available.

What is Ernexa Therapeutics’s dividend yield?

Ernexa Therapeutics does not currently have a dividend yield.

Ernexa Therapeutics(NASDAQ) ERNAW

Ernexa Therapeutics Financials at a Glance

ERNAW News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Ernexa Therapeutics

ERNAW Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Ernexa Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About ERNAW

What is the current price of Ernexa Therapeutics?

What is the 52-week range for Ernexa Therapeutics?

How much debt does Ernexa Therapeutics have?

How much cash does Ernexa Therapeutics have on hand?

What is Ernexa Therapeutics’s dividend yield?

Premium Investing Services